LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Saliva-Based ELISA Tests Measure COVID Neutralizing Antibodies in Multiple Samples at Same Time

By LabMedica International staff writers
Posted on 04 Apr 2022
Print article
Image: Saliva-based ELISA test detects neutralizing activity in response to COVID-19 vaccination (Photo courtesy of ReaGene Innovations)
Image: Saliva-based ELISA test detects neutralizing activity in response to COVID-19 vaccination (Photo courtesy of ReaGene Innovations)

After any vaccine against the SARS-CoV-2 virus, the body develops neutralizing antibodies which help fight the virus and is thus protective against infections and disease. The degree of protection offered by the vaccine depends on the neutralizing antibodies that are generated by the individual’s immune system. After some time, the neutralizing antibody decreases, and booster doses may be required. Now, two new high-throughput saliva-based ELSIA assays can detect neutralizing activity of samples in response to COVID-19 vaccination.

ReaGene Innovations (Hyderabad, India) has entered into a partnership with Lay Sciences, Inc. (Jupiter, FL, USA) for the development of two patent-pending ELISA and FAST FLOW SPOT diagnostic tests to detect neutralizing activity of samples in response to COVID 19 vaccination. The ELISA diagnostic test can be used in a hospital or pathology lab setting to quantitatively assess multiple samples at the same time. The FAST FLOW SPOT diagnostic test is a single user test that can be used by individuals in a “home” setting. Both diagnostics differ from other tests that measure neutralizing antibodies in blood samples because they only need the individual’s saliva sample. ReaGene will receive royalty payments from Lay Sciences upon the successful launch of the ELISA as well as the FAST FLOW SPOT diagnostic tests.

“Collaboration is important as it requires a concerted team effort to fight and win against a virus like COVID-19 the likes of which we have never seen before. I am also delighted that with the support of Lays Science, we will be able to globally launch these two tests, and which will help us in our fight against COVID-19,” said Dr. Uday Saxena, Scientific Co-Founder of ReaGene Innovations, who led these discoveries.

“These saliva based ELISA and FAST FLOW SPOT diagnostic tests offer yet another line of defense against the onslaught of rapidly evolving SARS-CoV-2 viral variants. These two diagnostic tests are simple and easy-to-use, and this partnership reiterates Lays Sciences’ commitment to fight COVID-19,” added Dr. Satish Chandran, Chief Executive Officer of Lay Science.

Related Links:
ReaGene Innovations
Lay Sciences, Inc. 

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.